Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.Appetite Stimulants: Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and AIDS.Wasting Syndrome: A condition of involuntary weight loss of greater then 10% of baseline body weight. It is characterized by atrophy of muscles and depletion of lean body mass. Wasting is a sign of MALNUTRITION as a result of inadequate dietary intake, malabsorption, or hypermetabolism.Muscular Atrophy: Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.Megestrol Acetate: Megestrol acetate is a progestogen with actions and uses similar to those of the progestogens in general. It also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia. (From Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)Muscle, Skeletal: A subtype of striated muscle, attached by TENDONS to the SKELETON. Skeletal muscles are innervated and their movement can be consciously controlled. They are also called voluntary muscles.Weight Loss: Decrease in existing BODY WEIGHT.Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Receptor, Melanocortin, Type 4: A melanocortin receptor subtype found primarily in BRAIN. It shows specificity for ALPHA-MSH; BETA-MSH and ADRENOCORTICOTROPIC HORMONE.Ghrelin: A 28-amino acid, acylated, orexigenic peptide that is a ligand for GROWTH HORMONE SECRETAGOGUE RECEPTORS. Ghrelin is widely expressed but primarily in the stomach in the adults. Ghrelin acts centrally to stimulate growth hormone secretion and food intake, and peripherally to regulate energy homeostasis. Its large precursor protein, known as appetite-regulating hormone or motilin-related peptide, contains ghrelin and obestatin.Nutritional Support: The administration of nutrients for assimilation and utilization by a patient by means other than normal eating. It does not include FLUID THERAPY which normalizes body fluids to restore WATER-ELECTROLYTE BALANCE.Interleukin-6: A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS.Eating: The consumption of edible substances.Melanocortins: Peptides derived from pro-opiomelanocortin (POMC) which can stimulate MELANOCYTES or CORTICOTROPHS. Melanocortins include ACTH; ALPHA-MSH; and other peptides such as BETA-MSH and GAMMA-MSH, derived from other fragments of POMC. These peptides act through a variety of MELANOCORTIN RECEPTORS to control different functions including steroidogenesis, energy homeostasis, feeding, and skin pigmentation.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Dictionaries, MedicalDictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Dictionaries, ChemicalPhonetics: The science or study of speech sounds and their production, transmission, and reception, and their analysis, classification, and transcription. (Random House Unabridged Dictionary, 2d ed)Language: A verbal or nonverbal means of communicating ideas or feelings.Speech: Communication through a system of conventional vocal symbols.Hippocratic Oath: An oath, attributed to Hippocrates, that serves as an ethical guide for the medical profession.History, Ancient: The period of history before 500 of the common era.Philosophy, MedicalHistory, 17th Century: Time period from 1601 through 1700 of the common era.Syndrome: A characteristic symptom complex.History, Medieval: The period of history from the year 500 through 1450 of the common era.DictionaryTerminology as Topic: The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Medicine in Literature: Written or other literary works whose subject matter is medical or about the profession of medicine and related areas.Research: Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)Forecasting: The prediction or projection of the nature of future problems or existing conditions based upon the extrapolation or interpretation of existing scientific data or by the application of scientific methodology.Access to Information: Individual's rights to obtain and use information collected or generated by others.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Journal Impact Factor: A quantitative measure of the frequency on average with which articles in a journal have been cited in a given period of time.Peer Review, Research: The evaluation by experts of the quality and pertinence of research or research proposals of other experts in the same field. Peer review is used by editors in deciding which submissions warrant publication, by granting agencies to determine which proposals should be funded, and by academic institutions in tenure decisions.Publishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.Cell Adhesion: Adherence of cells to surfaces or to other cells.Dietary Supplements: Products in capsule, tablet or liquid form that provide dietary ingredients, and that are intended to be taken by mouth to increase the intake of nutrients. Dietary supplements can include macronutrients, such as proteins, carbohydrates, and fats; and/or MICRONUTRIENTS, such as VITAMINS; MINERALS; and PHYTOCHEMICALS.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Resistance Training: A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Melatonin: A biogenic amine that is found in animals and plants. In mammals, melatonin is produced by the PINEAL GLAND. Its secretion increases in darkness and decreases during exposure to light. Melatonin is implicated in the regulation of SLEEP, mood, and REPRODUCTION. Melatonin is also an effective antioxidant.Appetite: Natural recurring desire for food. Alterations may be induced by APPETITE DEPRESSANTS or APPETITE STIMULANTS.Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Health Facility Merger: The combining of administrative and organizational resources of two or more health care facilities.Library Services: Services offered to the library user. They include reference and circulation.Archaeology: The scientific study of past societies through artifacts, fossils, etc.Radiometric Dating: Techniques used to determine the age of materials, based on the content and half-lives of the RADIOACTIVE ISOTOPES they contain.

Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. (1/649)

Interleukin 6 (IL-6) is a multifunctional cytokine. Recent reports suggest that circulating IL-6 secreted from tumour cells plays an important role in cancer-induced cachexia. Medroxyprogesterone acetate (MPA) has been used as an endocrine therapeutic agent for patients with breast cancer. It has been suggested that MPA decreases serum IL-6 levels and preserves the bodyweight of patients with advanced breast cancer. However, the mechanisms of action responsible for the anticachectic effect of MPA have not been elucidated. Therefore, the effects of MPA on IL-6 secretion were studied both in vitro and in vivo using a human breast cancer cell line, KPL-4, which secretes IL-6 into medium and induces cachexia when injected into female nude mice. MPA (10-1000 nM) dose-dependently decreased basal IL-6 secretion into medium, and also suppressed tumour necrosis factor (TNF-alpha)-induced IL-6 secretion. Both basal and TNF-alpha-induced IL-6 mRNA levels were dose-dependently lowered by MPA. Moreover, intramuscular injections of MPA (100 mg kg(-1) twice a week) into nude mice bearing KPL-4 transplanted tumours significantly decreased serum IL-6 levels without affecting tumour growth and preserved the bodyweight of recipient mice. These findings suggest that suppression of IL-6 secretion from tumour cells, at least in part, causes the anticachectic effect of MPA.  (+info)

Tumour inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma. (2/649)

Murine colon 26 carcinoma growing at either subcutaneous (s.c.) or intramuscular (i.m.) inoculation sites causes cachexia in mice. Such animals show extensive loss of body weight, wasting of the muscle and adipose tissues, hypoglycaemia, and hypercalcaemia, even when the tumour weight comprises only about 1.9% of carcass weight. In contrast, the same tumour when inoculated into the liver does not cause any sign of tumour-related cachexia even when the tumour becomes much larger (6.6% of carcass weight). Interleukin 6 (IL-6), a mediator associated with cachexia in this tumour model, is detected at high levels both in the tumour tissues and in the circulating blood of mice bearing colon 26 tumour at the s.c. inoculation site. In contrast, only minute levels of IL-6 are detected in the tumour grown in the liver. The colon 26 tumour grown in the liver does not lose its ability to cause cachexia, because the tumour when re-inoculated s.c. is able to cause extensive weight loss and produce IL-6 as did the original colon 26 cell line. Histological studies revealed differences in the composition of tumour tissues: the tumours grown in the subcutis consist of many polygonal tumour cells, extended-intercellular space, and high vascular density, whereas those grown in the liver consist of spindle-shaped tumour cells. Thus, the environment where tumour cells grow would be a critical factor in determining the cachectic phenotype of cancer cells, including their ability to produce IL-6.  (+info)

Alterations of lipid and cholesterol metabolism in cachectic tumor-bearing rats are prevented by insulin. (3/649)

The ascites hepatoma Yoshida AH130 causes in the host a rapid and progressive body weight loss, associated with reduced food intake, and protein and lipid hypercatabolism. Because insulin regulates glucose as well as lipid and protein metabolism, we suggest that the observed alterations are at least in part secondary to hypoinsulinemia and/or to the increase of counterregulatory hormones in AH130-bearing rats. To verify this hypothesis, controls with free access to food (n = 4), controls with free access to food plus insulin (107 micromol. kg body wt-1. d-1) (n = 4), controls pair-fed to the tumor-bearing rats (n = 4), pair-fed controls treated with insulin (n= 4), tumor hosts (n = 9), and tumor hosts treated with insulin (n = 6) were used. The Yoshida ascites hepatoma cells ( approximately 10(8) cells/rat) were inoculated intraperitoneally. Daily food intake and body weight were measured; insulin was injected starting the day of tumor implantation for 6 d. The metabolism of both cholesterol and lipids was investigated in tumor cells, and ascitic fluid and blood serum were investigated at the end of treatment. Insulin prevented the reduction of food intake (19 +/- 0.6 vs. 13 +/- 0.4 g/d, P < 0.01; AH130 hosts treated and not treated with insulin, respectively), the loss of body weight (202 +/- 12 vs. 135 +/- 9 g, P < 0.01), lowered the circulating triglycerides (48.3 +/- 4.9 vs. 84.5 +/- 7.1 mmol/L, P < 0.01), and free fatty acids (561 +/- 47 vs. 989 +/- 54 mmol/L (P < 0.01), while corrected the decrease of adipose lipoprotein lipase activity (1,240 +/- vs. 300 +/- pmol FA, P < 0.01) observed in AH130 hosts. Moreover, insulin prevented the decrease in HDL cholesterol (13.2 +/- 0.8 vs. 9.3. +/- 0.7 mmol/L, P < 0.01) and significantly increased hepatic cholesterol synthesis as evaluated by 14C-acetate incorporation into cholesterol, in both liver (3,337 +/- 245 vs. 830 +/- 115 Bq/g, P < 0.01) and AH130 cells (11,676 +/- 1,693 vs. 4,196 +/- 527 Bq/10(6) cells, P < 0.01). Thus insulin treatment ameliorated many metabolic derangements, with a lengthening of rats survival time (7 +/- 1 vs. 11 +/- 1 d, P < 0.05) without significantly stimulating tumor growth. These data, together with our previous observations on the effectiveness of insulin on protein turnover perturbations, suggest that many metabolic alterations occurring during cancer cachexia can be avoided by the administration of this hormone.  (+info)

Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. (4/649)

The steroid hormone 1,25-dihydroxyvitamin D [1,25(OH)2D, also known as calcitriol] is known to inhibit the proliferation and to promote the differentiation of human prostate cancer cells. Additionally, we showed that 1,25(OH)2D markedly inhibits the invasiveness of human prostate cancer cells in vitro (G. G. Schwartz et al., Cancer Epidemiol. Biomark. Prev., 6: 727-732, 1997). These properties support the use of 1,25(OH)2D as differentiation therapy in prostate cancer. However, the use of 1,25(OH)2D in vivo is limited by the risk of hypercalcemia. We therefore compared the effects of 1,25(OH)2D and of EB1089, an analogue of 1,25(OH)2D with reduced calcemic effects, in an in vivo model of androgen-insensitive metastatic prostate cancer, the rat Dunning MAT LyLu prostate cancer model. Tumor growth and metastasis were studied using Copenhagen rats given s.c. injections of MAT LyLu cells. Fifty male rats were divided into five groups of 10 rats each. Four experimental groups received i.p. injections of low and high doses of 1,25(OH)2D and EB1089 (0.5 and 1.0 microg/kg, low and high, respectively). A control group received injections of vehicle only. Tumor volumes were measured three times per week. Rats were weighed weekly. The number of metastases to the lungs and the extent of hypercalcemia were evaluated. Compared with controls, tumor volumes were significantly smaller in all experimental groups. Similarly, the number of lung metastases (number of foci/lung) was reduced markedly by both 1,25(OH)2D and EB1089. Control rats developed 22.7 (+/- 1.98 SE) tumor foci per lung. Rats treated with 1,25(OH)2D and with EB1089 (1.0 microg/kg) developed 10.4 (+/- 2.81) and 7.70 (+/- 1.29) tumor foci, respectively (P < 0.001 and P < 0.0001, respectively; drug versus control). Compared with controls (10.79 +/- 0.1 mg/dl), serum calcium levels were significantly elevated in both 1,25(OH)2D and EB1089-treated rats (P < 0.01). However, EB1089 was significantly less calcemic than 1,25(OH)2D (12.59 +/- 0.21 mg/dl versus 14.47 +/- 0.46 mg/dl; 1.0 microg/kg; P < 0.001). Rats treated with 1,25(OH)2D showed marked weight loss: 20.0 +/- 1.9% and 26.3 +/- 1.7% of their initial weight (low and high doses, respectively, P < 0.001). Weight loss was significantly lower in rats treated with EB1089 at the high dose 8.4 (+/- 2.9) %. Moreover, rats treated with low-dose EB1089 gained 5.2 (+/- 3.7) % of their initial weight. In conclusion, 1,25(OH)2D and EB1089 showed marked and equivalent inhibition of prostate cancer metastasis in vivo. EB1089 was significantly less calcemic than 1,25(OH)2D and did not induce severe weight loss. This is the first report of a vitamin D analogue that significantly inhibits prostate cancer metastasis in vivo and that does so without producing cachexia or unacceptable hypercalcemia.  (+info)

Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. (5/649)

Cancer cachexia, characterized by anorexia, weight loss and progressive tissue wasting, has been postulated to be mediated by various cytokines. However, the precise mechanism of cachexia induction is not fully explained. We have developed synthetic double-stranded oligodeoxynucleotides (ODN) as 'decoy' cis-elements that block the binding of nuclear factors to promoter regions of targeted genes, resulting in the inhibition of gene transactivation in vivo as well as in vitro. This novel molecular strategy could be useful for treating a broad range of human diseases including cancer. In this study, we injected decoy ODN targeting the transcriptional factor, NF-kappa B (NF kappa B) binding cis-elements, which are essential for transactivation of gene expression of cytokines, directly into tumors of adenocarcinoma colon26 in mice, in order to examine whether or not cachexia is alleviated by inhibiting the action of cytokines. Tumor growth was not affected by transfection of NF kappa B decoy ODN as compared with scrambled decoy ODN. Nevertheless, transfection of NF kappa B decoy, but not scrambled decoy, ODN resulted in attenuation of the reductions in body weight, epididymal fat, gastrocnemius muscle mass and food intake, which were induced by the tumor presence. Interleukin 6 mRNA in the tumor was also markedly decreased by the transfection of NF kappa B decoy ODN. It is known that the transcriptional factor E2F plays a pivotal role in the coordinated transactivation of cell cycle regulatory genes. Therefore, we hypothesized that the introduction of synthetic double-stranded DNA with high affinity for E2F in vivo as 'decoy' cis-elements might inhibit the tumor growth of colon26, resulting in turn in inhibition of cachexia induction. However, injection of E2F decoy ODN failed to inhibit tumor growth and cachexia induction, as compared with mismatched decoy ODN. Overall, the present study demonstrated that cachexia induced by adenocarcinoma colon26 was inhibited by blocking of NF kappa B, using a novel molecular decoy strategy, without an effect on tumor growth, and also that tumor growth and cachexia induction in the colon26 model were not affected by E2F decoy ODN. These results suggest that cytokines regulated by NF kappa B may play a pivotal role in the induction of cachexia by colon26, providing a new therapeutic strategy for cancer cachexia.  (+info)

Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. (6/649)

The effect of a proteolysis-inducing factor (PIF), produced by cachexia-inducing tumours on glucose utilization by different tissues and the effect of pretreatment with the polyunsaturated fatty acid eicosapentaenoic acid (EPA), has been determined using the 2-deoxyglucose tracer technique. Mice receiving PIF showed a profound depression of body weight (2.3 g) over a 24-h period, which was completely abolished by pretreatment with a monoclonal antibody to PIF or by 3 days pretreatment with EPA at 500 mg kg(-1). Animals receiving PIF exhibited a marked hypoglycaemia, which was effectively reversed by both antibody and EPA pretreatment. There was an increase in glucose utilization by brain, heart and brown fat, but a decrease by kidney, white fat, diaphragm and gastrocnemius muscle after administration of PIF. Changes in organ glucose consumption were attenuated by either monoclonal antibody, EPA, or both. There was a decrease in 2-deoxyglucose uptake by C2C12 myoblasts in vitro, which was attenuated by EPA. This suggests a direct effect of PIF on glucose uptake by skeletal muscle. These results suggest that in addition to a direct catabolic effect on skeletal muscle PIF has a profound effect on glucose utilization during cachexia.  (+info)

Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. (7/649)

The aim of the present study was to investigate, in human lung cancer, the relationship between weight loss and the existence of a low body cell mass (BCM) on the one hand, and the putative presence of systemic inflammation, an increased acute-phase response, anorexia, hypermetabolism and changes in circulating levels of several anabolic and catabolic hormones on the other. In 20 male lung cancer patients, pre-stratified by weight loss of >/=10% (n=10) or of <10% (n=10), the following measurements were performed: BCM (by dual-energy X-ray absorptiometry/bromide dilution), circulating levels of sTNF-R55 and sTNF-R75 (soluble tumour necrosis factor receptors of molecular masses 55 and 75 kDa respectively), interleukin-6, lipopolysaccharide-binding protein, albumin, appetite (scale of 0-10), resting energy expenditure (by indirect calorimetry) and circulating levels of catabolic (cortisol) and anabolic [testosterone, insulin-like growth factor-I (IGF-I)] hormones. Compared with the patients with a weight loss of <10%, those with a weight loss of >/=10% were characterized by higher levels of sTNF-R55 (trend towards significance; P=0.06), and lower levels of albumin (27.4 compared with 34.4 mmol/l; P=0.02), testosterone (13.2 compared with 21.5 nmol/l; P=0.01) and IGF-I (119 compared with 184 ng/ml; P=0.004). In the patient group as a whole, the percentage weight loss was significantly correlated with sTNF-R55 (r=0.59, P=0.02), albumin (r=-0.63, P=0.006) and IGF-I (r=-0.50, P=0.02) levels. Height-adjusted BCM was significantly correlated with sTNF-R55 (r=-0.57, P=0.03), sTNF-R75 (r=-0.50, P=0. 04), lipopolysaccharide-binding protein (r=-0.50, P=0.04), albumin (r=0.56, P=0.02) and resting energy expenditure/BCM (r=-0.54, P=0. 03), and there was a trend towards a correlation with IGF-I concentration (r=0.44, P=0.06). We conclude that, in human lung cancer, weight loss and the presence of a low BCM are associated with systemic inflammation, an increased acute-phase response and decreased levels of IGF-I. In addition, a decreased BCM is associated with hypermetabolism.  (+info)

Differential reconstitution of mitochondrial respiratory chain activity and plasma redox state by cysteine and ornithine in a model of cancer cachexia. (8/649)

The mechanism of wasting, as it occurs in malignant diseases and various etiologically unrelated conditions, is still poorly understood. We have, therefore, studied putative cause/effect relationships in a murine model of cancer cachexia, C57BL/6 mice bearing the fibrosarcoma MCA-105. The plasma of these mice showed decreased albumin and increased glutamate levels, which are typically found in practically all catabolic conditions. Skeletal muscles from tumor-bearing mice were found to have an abnormally low mitochondrial respiratory chain activity (mito.RCA) and significantly decreased glutathione (GSH) levels. The decrease in mito.RCA was correlated with an increase in the i.m. GSH disulfide/GSH ratio, the plasma cystine/thiol ratio, and the GSH disulfide/GSH ratio in the bile. This is indicative of a generalized shift in the redox state extending through different body fluids. Treatment of tumor-bearing mice with ornithine, a precursor of the radical scavenger spermine, reversed both the decrease in mito.RCA and the change in the redox state, whereas treatment with cysteine, a GSH precursor, normalized only the redox state. Treatment of normal mice with difluoromethyl-ornithine, a specific inhibitor of ornithine decarboxylase and spermine biosynthesis, inhibited the mito.RCA in the skeletal muscle tissue, thus illustrating the importance of the putrescine/spermine pathway in the maintenance of mito.RCA. Ornithine, cysteine, and N-acetyl-cysteine (NAC) also reconstituted the abnormally low concentrations of the GSH precursor glutamate in the skeletal muscle tissue of tumor-bearing mice. Higher doses, however, enhanced tumor growth and increased the plasma glucose level in normal mice. In the latter, cysteine and NAC also decreased i.m. catalase and GSH peroxidase activities. Taken together, our studies on the effects of ornithine, cysteine, and NAC illuminate some of the mechanistic pathways involved in cachexia and suggest targets for therapeutic intervention.  (+info)

Aim: Explore the prevalence, experience and clinical implications of cardiac cachexia for patients with heart failure. A mixed methods cross-sectional study involving 3 phases.. Phase 1: Assess a sample (n=357) patients with advanced heart failure for signs of cachexia. Three validated questionnaires will be completed ( FACIT- fatigue, EuroQol 5- quality of life, FAACT- Functional assessment).. Phase 2: Semi-structured interviews with patients identified with cardiac cachexia ( n=12) and their caregiver ( n=12). Phase 3: Workshop with key stakeholders to discuss findings and determine practice & future research implications. ...
Rheumatoid arthritis (RA) is a chronic inflammatory disease in which pro-inflammatory cytokines, including tumor necrosis factor (TNF)-alpha, play a crucial role. The chronic inflammation, combined with reduced physical activity, leads to muscle wasting whereas fat mass would be maintained; the resulting abnormal metabolic state is described as rheumatoid cachexia. Since the loss of muscle volume would be compensated by the increased fat mass, body mass index (BMI) is reported not to reflect the nutritional status in RA patients. The implication of rheumatoid cachexia for cardiovascular risk and clinical prognosis is not clearly understood, however, adequate control of disease activity in combination with appropriate physical exercise could be the most important strategy to control rheumatoid cachexia and related metabolic problems.
Cachexia is a multifactorial syndrome that manifests during the advanced stage of chronic diseases and is characterized by a progressive loss of body mass sustained by underlying inflammation. The ApcMin/+ mouse is an established model of cachexia that exhibits a gradual loss of body mass correlating with increasing tumor burden and plasma IL - 6 levels. Moreover it also mimics other secondary characteristics observed in cachectic patients like splenomegaly, elevated plasma endotoxin levels, gut barrier dysfunction, hypogonadism and an overall hypermetabolic state. Liver controls the energy metabolism in the body by regulating glucose and lipid metabolism, glycogen storage, filtration of toxins from the portal blood, secretion of essential plasma protein like albumin and other acute phase proteins. As cachexia development results from sustained elevated energy demands, it can be speculated that liver might play a role in development of cachexia progression. The purpose of this study thus was to examine
Cancer cachexia is characterized by a hypermetabolic state that leads to catabolism that is responsible for reductions in lean mass.These catabolic changes are accompanied by an increase in total energy expenditure, but a decrease in voluntary energy expenditure that ultimately results clinically in cachexia and its symptoms of lethargy, fatigue, weakness and general malaise (Kotler DP. Cachexia. Ann Intern Med. 2000; 133:622-634).. The prevalence of cachexia increases from 50 percent at presentation to more than 80 percent before death from malignancy. In over 20 percent of cancer patients, cachexia is the cause of death (Bruera E. Anorexia, cachexia and nutrition. Br Med J 1997;315:1219-1222). Cancer cachexia leads to shorter survival, decreased response rates and increased toxicity to chemotherapy, weakness, and an overall decreased quality of life (DeWys et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 ...
Cancer cachexia is characterized by a hypermetabolic state that leads to catabolism that is responsible for reductions in lean mass.These catabolic changes are accompanied by an increase in total energy expenditure, but a decrease in voluntary energy expenditure that ultimately results clinically in cachexia and its symptoms of lethargy, fatigue, weakness and general malaise (Kotler DP. Cachexia. Ann Intern Med. 2000; 133:622-634).. The prevalence of cachexia increases from 50 percent at presentation to more than 80 percent before death from malignancy. In over 20 percent of cancer patients, cachexia is the cause of death (Bruera E. Anorexia, cachexia and nutrition. Br Med J 1997;315:1219-1222). Cancer cachexia leads to shorter survival, decreased response rates and increased toxicity to chemotherapy, weakness, and an overall decreased quality of life (DeWys et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 ...
In a recent study (Zhou et al., 2010), the authors defined the mechanism by which ActRIIB and its ligands regulate cachexia by studying multiple mouse models of cancer. They also investigated the potential therapeutic effects on cancer cachexia of blocking signaling through the ActRIIB signaling pathway. To antagonize the ActRIIB pathway, they engineered a decoy receptor containing the extracellular portion of human ActRIIB fused to the Fc region of IgG2, designated sActRIIB (soluble ActRIIB-Fc). The authors administered this decoy receptor to antagonize the ActRIIB pathway in four distinct mouse models of lethal cancer cachexia: colon26 (C26) murine adenocarcinoma-bearing mice, inhibin-α knockout mice (which develop gonadal tumors) and immunocompromised nude mice bearing either human G361 melanoma or TOV-21G ovarian carcinoma xenografts. By testing diverse models of cancer cachexia with tumors of distinct origin, the authors minimized the possibility that the tumor site or type would influence ...
In a Drosophila model of cancer-induced cachexia, the growth of a tumor (green, right) causes wasting of ovarian tissue (magenta) as compared to a normal host (left).
Mantovani G, Macciò A, Massa E, et al. Managing cancer-related anorexia/cachexia. Drugs. 2001;61:499-514. Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol. 2003;21:129-134. Barber MD. Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation. Nutrition. 2001;17:751-755. Tisdale MJ, Dhesi JK. Inhibition of weight loss by omega-3 fatty acids in an experimental cachexia model. Cancer Res. 1990;50:5022-5026. Yang M, Cook ME. Dietary conjugated linoleic acid decreased cachexia, macrophage tumor necrosis factor-alpha production, and modifies splenocyte cytokines production. Exp Biol Med (Maywood). 2003;228:51-58. Tisdale MJ, Brennan RA. A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model. Br J Cancer. 1988;58:580-583. Inui A. Cancer anorexia-cachexia ...
Despite the relatively low plasma glucose levels in many cachectic patients, a factor that usually stimulates appetite, a typical characteristic of cachexia is anorexia or loss of appetite. This symptom ...
Although heart failure has traditionally been regarded as a circulatory disorder, physicians have recognized for more than 2500 years that patients with heart failure share many of the clinical features of those afflicted with chronic inflammatory or neoplastic diseases.1 2 As heart failure advances, many patients develop a syndrome known as cardiac cachexia, which is characterized by a profound loss of lean body mass and anorexia and is accompanied by many of the biochemical changes of malnutrition (anemia, hypoalbuminemia, leukopenia, and hypocholesterolemia) and inflammation (increased erythrocyte sedimentation rate, fibrinogen, and acute-phase reactants).3 4 The pathogenesis of cardiac cachexia remained obscure for many years, until it was recognized that patients with cardiac cachexia have high circulating levels of tumor necrosis factor (TNF).5 This pluripotent cytokine causes cachexia, anorexia, and inflammation during long-term administration to experimental animals,6 and high ...
TY - JOUR. T1 - Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. AU - Bing, Chen. AU - Bao, Yi. AU - Jenkins, John. AU - Sanders, Paul. AU - Manieri, Monia. AU - Cinti, Saverio. AU - Tisdale, Michael J.. AU - Trayhurn, Paul. PY - 2004/2/24. Y1 - 2004/2/24. N2 - Zinc-α2-glycoprotein (ZAG), a 43-kDa protein, is overexpressed in certain human malignant tumors and acts as a lipid-mobilizing factor to stimulate lipolysis in adipocytes leading to cachexia in mice implanted with ZAG-producing tumors. Because white adipose tissue (WAT) is an endocrine organ secreting a wide range of protein factors, including those involved in lipid metabolism, we have investigated whether ZAG is produced locally by adipocytes. ZAG mRNA was detected by RT-PCR in the mouse WAT depots examined (epididymal, perirenal, s.c., and mammary gland) and in interscapular brown fat. In WAT, ZAG gene expression was evident in mature adipocytes and in ...
The development of espindolol for the treatment of cancer cachexia entered a new phase this month, with the formation of a new spin out company Actimed Therapeutics. Actimed was founded by Profs Andrew Coats and Stefan Anker, two leading cardiologists and inventors of the background intellectual property for the use of beta adrenergic blockers in the treatment of cachexia. Numedicus improved on this technology in the identification of a single isomer of pindolol, and the filing of a patent (now granted worldwide) for the treatment of cachexia.. Espindolol is an improvement on the general utility of beta blockade, since it combines three mechanisms of action in one molecule: beta-1 adrenergic inhibition for the prevention of excess catabolism, partial beta-2 adrenergic agonism to promote anabolism and interaction with 5-HT1A receptors to combat fatigue. In in vivo testing, espindolol outperformed all other beta blockers in various measures of cachexia; and in a Phase IIb clinical trial, ...
DESCRIPTION provided by applicant Chronic kidney disease CKD is a major public health problem in the US with an estimated prevalence of million patients enter hemodialysis or peritoneal dialysis programs yearly A serious complication in of patients with CKD is cachexia or muscle wasting which decreases quality of life and increases morbidity and mortality Unfortunately there are no agents available in the clinic to treat CKD induced cachexia We determined that expression of myostatin a member of the TGF peptide hormone family and the major negative regulator of muscle mass is increased in the skeletal muscles of patients and mice with CKD Blocking myostatin in CKD mice with a humanized myostatin peptibody prevented CKD induced cachexia raising the possibility of using it to treat cachexia in CKD patients However a similar myostatin targeting strategy was halted in Phase I due to unexplained nose and gum bleeding We discovered that CKD in patients and mice activates signal transducer and ...
Background Cancer cachexia, mainly characterized by muscle atrophy and subsequent cancer induced weight loss (CIWL), is attributed to about a third of cancer deaths. Despite worsening prognoses with the symptoms, clinical factors involved and the effect of CIWL to the overall status remain unexplained. We planned a prospective cohort study, Japan Nutrition and QOL survey in patients with advanced NSCLC study to investigate changes in CIWL in relation to grip, QOL, and clinical parameters to understand their effects on prognosis.. Method Untreated stage IV NSCLC patients with ECOG PS of 0-2 were registered. Their body weight (BW), grip, QOL, Karnofsky Performance Scale, biochemical assay, and survival were recorded every four weeks for one year from the start of cancer treatments. Patients were classified by BW loss ≥ 5% and cachexia diagnosis by BW loss, fatigue, anorexia, and abnormal assay results. Estimated survival curves were drawn by Kaplan-Meier method, and Log-rank test was applied. To ...
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting [email protected] All previous versions of the manuscript and all author responses to the reviewers are also available.. You can find further information about the peer review system here.. ...
Removal of all RCC cases, and accumulation of appropriately functioning nephrons. In three half-lives, cachectic patients, and the murine-derived agents (0% human) and thus preventing carboxylation of drug concentration levlen ed pill cost can be effective in FH patients compared with normolipidemic individuals. Most recently, in the collecting system. Additionally, levlen ed pill cost challenge dosing with 35 mg of antimicrobial combinations are most frequently observed with the available data. ST segment changes suggestive of many infection outcomes. A Pew Research Center survey in the entire cohort at 24 months was 43%. Activation of patients with the patient with SJS/TEN has contained concentrations of a conformational change in high titers and may levlen ed pill cost be considered. The cause of AMS, oxygenation, as high as bromocriptine for testing the ultrasound beam adequate levlen ed pill cost access to the time for actual delivery is a functioning kidney transplant. The principal ...
Purpose: Cachexia is a complex metabolic syndrome associated with underlying illness and characterized by reduced muscle mass and in some studies also reduced fat mass. Cachexia is defined by unintentional non-oedematous weight loss of at least 5 % in ≤ 12 months. No prospective studies have evaluated changes in body composition over time. Thus we studied, in a prospective manner, alterations in body composition in patients with heart failure (HF) with and without cardiac cachexia.. Methods: From 2009-2011 we screened 627 HF patients and identified 19 with reduced left ventricular ejection fraction (LVEF) and cachexia as defined. They were matched with 19 HF patients without cachexia with a single match by kidney function, age and gender. Body composition was assessed 3 times during 12 months by dual energy x-ray absorptiometry (DXA) measuring muscle and fat mass as well as fat distribution (abdominal and gynoid fat). No changes in diuretic dosage were made in this period.. Results: The ...
Cancer cachexia is a complex metabolic disease accounting for approximately one third of all cancer-related deaths worldwide. So far, there is no effective therapy for this muscle wasting disease. Researchers from the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena, Germany, show that the extracellular ligand Wnt7a effectively counteracts muscle wasting through activation of the anabolic AKT/mTOR pathway and thereby reverts the loss of muscle stem cell functionality and muscle mass. The results have now been published in the journal Molecular Therapy: Oncolytics.. Jena. Cancer Cachexia often occurs in cancer patients in an advanced state. This metabolic wasting syndrome leads to severely reduced muscle mass and fat tissue, which cannot be reversed by nutritional support. Furthermore, muscle regeneration is affected during cancer cachexia due to impaired muscle stem cell function. A problem that also occurs often in the aging process. Cancer cachexia is associated with a poor ...
2019 The Author(s). Background: Most advanced elderly cancer patients experience fatigue, anorexia, and declining physical function due to cancer cachexia, for which effective interventions have not been established. We performed a phase I study of a new nonpharmacological multimodal intervention called the nutritional and exercise treatment for advanced cancer (NEXTAC) program and reported the excellent feasibility of and compliance with this program in elderly patients with advanced cancer who were at risk for cancer cachexia. We report here the background, hypothesis, and design of the next-step multicenter, randomized phase II study to evaluate the efficacy of the program, the NEXTAC-TWO study. Methods: Patients with chemo-naïve advanced non-small cell lung cancer or pancreatic cancer, age ≥ 70 years, performance status ≤2, with adequate organ function and without disability according to the modified Katz index will be eligible. In total, 130 participants will be recruited from 15 ...
Wheat germ is excessive in several important nutrients, corresponding to vitamin E, folic acid (folate), thiamin, zinc, magnesium, phosphorus, as well as fatty alcohols and important fatty acids. It pushes up the pre-programmed weight plateau of your body; the main perform nutritin seven- Keto is to stimulate the thyroid gland, as it is a pure thyroid supplement. A Low Glycemic Degree Weight loss program makes sense for anyone. Nonetheless, if you happen to endure from coronary artery disease cachexja have any coronary heart well being issues cancer cachexia and nutrition high ldl cholesterol, the advice continues to be to limit your dietary consumption of ldl cholesterol. You could encounter meals and water which might be impure, and you may need particular advice on what to do to stop issues. For vitamin D it is strongly recommended that we in the Northern Hemisphere complement with 2,000IU 12 months round if we do not get out a lot in the summertime or from cafhexia February to November ...
The Report Cancer Cachexia Pipeline Review, H2 2012 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz
The aim was to investigate the serum levels of leptin, TNF-alpha, IL-1 beta, IL-6, insulin, and growth hormone in patients with upper gastrointestinal cancer and cachexia. A total of 39 patients with various advanced stage (stage IV) gastrointestinal malignancies were enrolled. These cancer patients were divided into two groups according to the presence or absence of cachexia. Fifteen healthy adults were recruited as the control group. Body mass index (BMI; kg/m2) was calculated. Serum leptin, tumour necrosis factor (TNF)-α interleukin (IL)-1 beta, interleukin (IL)-6, growth hormone, insulin, glucose, triglyceride, total protein, albumin, erythrocyte sedimentation rate, and CRP were measured. In both cancer groups (cachectic and non-cachectic) body mass index and serum leptin levels were lower than controls (p , 0.001). Serum IL-1 beta, IL-6, and growth hormone levels were higher in both cachectic and non-cachectic groups than those of controls (p , 0.05). Serum TNF-α level in non-cachectic ...
A European animal study has found that L-carnitine supplementation could become part of treatment for cancer-related cachexia.. Cancer-related cachexia is a devastating wasting syndrome, where the sufferer experiences dramatic muscle loss and weight loss. This is caused by the bodys own immune system which is attempting to fight the cancer, but breaks down and destroys skeletal muscle and fat tissue.. It usually occurs in advanced cancer, and severely affects quality of life. Some patients with cancer cachexia become so frail they cannot even walk.. The National Cancer Institute estimates that about a third of all cancer deaths are caused by cancer cachexia. This is not only due to extreme frailty, but also because cachexia hinders treatment responses.. S Busquets, R Serpe, et al, part of the Cancer Research Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain, developed an animal trial to study the effects of L-carnitine on ...
TY - JOUR. T1 - Its more than low BMI. T2 - prevalence of cachexia and associated mortality in COPD. AU - McDonald, Merry-Lynn N.. AU - Wouters, Emiel F. M.. AU - Rutten, Erica. AU - Casaburi, Richard. AU - Rennard, Stephen. AU - Lomas, David A.. AU - Bamman, Marcas. AU - Celli, Bartolome. AU - Agusti, Alvar. AU - Tal-Singer, Ruth. AU - Hersh, Craig P.. AU - Dransfield, Mark. AU - Silverman, Edwin K.. PY - 2019/5/22. Y1 - 2019/5/22. KW - COPD. KW - Cachexia. KW - BODE. KW - Weight loss. KW - BMI. KW - FAIL. U2 - 10.1186/s12931-019-1073-3. DO - 10.1186/s12931-019-1073-3. M3 - Article. VL - 20. JO - Respiratory Research. JF - Respiratory Research. SN - 1465-9921. M1 - 100. ER - ...
According to the most recent consensus statement (Muscaritoli et al 2010), cachexia can be defined as weight loss exceeding 5% within the previous 3-12 months in patients with long term chronic conditions OR BMI < 20 kg/m², combined with symptoms characteristic for cachexia,
Meaning: bad general state of health, 1550s (from 1540s in Englished form cachexy), from Latinized form of Greek kakhexia bad… See more.
Marijuana is gaining a reputation as the best treatment for Cachexia and Wasting. Get your medical marijuana card for Wasting and Cachexia from licensed 420 MD.
Cancer cachexia is characterized as a multifactorial syndrome defined by an ongoing loss of adipose and skeletal muscle mass that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Current data indicate that more than half of all cancer patients show evidence of the cachexia syndrome, leading to substantial impairment of respiratory muscle function and contributing to poor quality of life and decreased survival.. ...
Cancer cachexia is characterized as a multifactorial syndrome defined by an ongoing loss of adipose and skeletal muscle mass that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Current data indicate that more than half of all cancer patients show evidence of the cachexia syndrome, leading to substantial impairment of respiratory muscle function and contributing to poor quality of life and decreased survival.. ...
Virtually all patients with pancreatic cancer develop weight loss and this can progress to significant muscle wasting (cachexia). Such cachexia is associated with reduced treatment tolerance, quality of life and survival. At the same time, more than a third of pancreatic cancer patients are either overweight/obese or have clinical/sub-clinical diabetes. Obesity can mask the development of muscle wasting and, in theory may even act along with diabetes to accelerate loss of skeletal muscle. At present there is no approved treatment for the management of cancer cachexia. Fatty muscle (myosteatosis) is a feature of obesity, diabetes and cancer cachexia and has recently been associated with markedly shortened survival in cancer patients. However, it is not known whether in patients with pancreatic cancer, the accumulation of fat in muscle plays a primary role in muscle wasting or is simply a bystander. The present project seeks to explore this relationship by determining whether there is an ...
Hippocrates described a syndrome of wasting and progressive inanition among patients who were ill and dying. The Greek words kakos, meaning bad things, and hexus, meaning state of being, have led to the term cachexia to describe this syndrome. Cachex
The present invention relates to therapy and the use of agents in the therapy of cachexia and wasting syndromes due to diseases other than congestive heart failure. Cachexia occurs in a number of other chronic diseases, like liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis. Cachexia and weight loss are linked to inflammatory processes and they are linked to increased mortality and/or morbidity. Cytokine activation is a potential causal mechanism for the development of cachexia also in these other diseases. The invention describes a method of treating or ameliorating body wasting or cachexia in a patient with liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis in a patient. The method comprises administering to the patient an effective amount of a compound that is able to reduce the production, absorption and/or the effect of an endotoxin (lipopolysaccharide; LPS). The invention
Numedicus is please to note the report from PsiOxus, on the outcome of a Phase II trial of MT-102, or s-pindolol, in cancer cachexia. David Cavalla is inventor of this technology (see EP2094254B1).. MT-102 is a first-in-class product in this difficult indication, demonstrating significant benefit against the primary endpoint, weight loss/gain. In a trial of 87 patients over 16 weeks, involving 2 dose levels plus placebo, patients on the higher dose of active drug actually gained weight relative to the loss of weight suffered in the placebo group.. Pharmacologically, MT-102 does three things: oppose excess catabolic drive via beta-1 adrenergic antagonism, increase tissue anabolism via partial beta-1 adrenergic agonism, and antagonise fatigue via 5-HT1A receptors. No other existing compound has this profile, and it previously proved superior to all other tested beta blockers (including racemic pindolol) in preclinical models.. ...
Background Anorexia Cachexia syndrome (ACS) is a common and devastating condition in cancer patients. It is poorly defined and heterogeneous, with many difficulties in conducting research and translating those findings into practice. A literature review revealed that patients experience of the care offered by healthcare professionals was generally negative. Professionals were seen to avoid the issue or offer scanty/ineffective advice. It was hypothesised that proactive, systematic management could overcome some of these barriers. This was seen in an interventional study of such an approach, QISAM (Quantifying the impact of Standardised Assessment and Management).. ...
Skeletal muscle atrophy is a major health concern and can be caused by denervation, immobility, or chronic disease states, such as diabetes and cancer. Previous work had found that the denervated muscles were more responsive to the cytokine TWEAK, and the same group now reports that the scaffold and ubiquitin ligase TRAF6 is involved in the activation of various signaling molecules implicated in muscle atrophy, including c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (p38 MAPK), AMP-activated protein kinase (AMPK), and nuclear factor κB (NF-κB). TRAF6 was abundant in undifferentiated myoblasts (C2C12) and in developing skeletal muscle of young mice, but its abundance decreased in differentiated myotubes (C2C12 cells) and in adult mice. In multiple paradigms that cause muscle atrophy (denervation or mouse models of cancer-induced cachexia or diabetes), TRAF6 transcription, protein abundance, and ubiquitylation increased in the atrophying muscles. Although muscle-specific ...
JoVE publishes peer-reviewed scientific video protocols to accelerate biological, medical, chemical and physical research. Watch our scientific video articles.
Cachexia, recognized by progressive loss of skeletal muscle and adipose tissue, contributes directly to morbidity and mortality in diseases as diverse as organ failure, AIDS, burn, trauma and cancer. Indeed, cachexia itself and not other effects of the tumor is thought to be the cause of up to 1/3 of all cancer deaths. Relatively little is understood regarding the molecular and cellular pathways leading to weight loss and dysmetabolism in cachexia and currently there are no approved, effective therapies. My group, working with a large and diverse group of collaborators, seeks to fill that knowledge gap by using novel animal models and correlative phenotypic and molecular data from patients to identify molecular, cellular and organ system mechanisms leading to cachexia. In this fashion we have:. 1. Identified a key role for IL-6/GP80/GP130/STAT3 in muscle and fat wasting in cancer and burns.. 2. Identified a causal role for Activins in burn-induced muscle wasting and shown efficacy in targeting ...
Whenever cardiac insufficiency or serious heart defects worsen, such deterioration is often associated with a loss of muscular mass and muscular strength. Scientists at the Charité - Universitätsmedizin Berlin have now succeeded in identifying the mechanism that underlies this disease, also known as cardiac cachexia. On the basis of these latest findings it may now be possible to influence the processes that strengthen and accelerate protein degradation in the body with the help of certain medications.
...Cachexia or wasting is a condition affecting up to 70 percent of cance... Doctors used to believe that cancer re-programs metabolism in such a ...The researchers discovered that cancerous mice have extremely low lipi... This is a clear indication of a central gene switch in the liver driv...,Liver,controls,wasting,in,cancer,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
Aston University researchers are seeking industrial partners to develop an anti-obesity drug that exploits a fat-burning process that affects cancer patients. Weight loss is triggered by a protein, Zag (zinc alpha 2 glyco-protein), that is produced naturally in the body. Zag occurs in greater quantities in cancer patients. The protein allows weight loss with no change in eating habits. The protein was first discovered in 1962, but scientists have been unsure about its function until now. Research led by Mike Tisdale, professor of cancer biochemistry at Astons School of Life and Health Sciences, found that Zag acts in a similar way to hormones produced in the body that convert fat into heat rather than energy during exposure to cold. The discovery was made when the research team was studying cachexia syndrome, the process of weight-loss in cancer patients that can cause them to lose up to 85 per cent of their body fat. The researchers found that while Zag is present in normal tissue, its ...
The Report Cachexia Global Clinical Trials Review, H2, 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for...
bad general state of health, 1540s, from Mod.L. cachexia, from Gk. kakhexia bad habits, from kakos bad (see CACO (Cf. caco )) + exia, related to exis habit or state, from exein to have, be in a condition, from PIE root *segh
... definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look it up now!
Mediators of Inflammation is a peer-reviewed, Open Access journal that publishes original research and review articles on all types of inflammatory mediators, including cytokines, histamine, bradykinin, prostaglandins, leukotrienes, PAF, biological response modifiers and the family of cell adhesion-promoting molecules.
Just about every of those problems results in a metabolic adaptation of increased protein degradation (cachexia), lessened fee of muscle protein synthesis (inactivity), or an alteration in the two (sarcopenia). The scientific outcomes of bedrest may possibly mimic Individuals of cachexia, such as rapid loss of muscle mass, insulin resistance, and weakness. Prophylaxis against here bedrest-induced atrophy involves nourishment support with an emphasis on superior-excellent protein. Nutritional supplementation alone may well not reduce muscle mass loss secondary to cachexia, but, in combination with the use of an anabolic agent, it might slow or prevent muscle loss. Preceding SectionNext ...
Cachexia is a frequently observed syndrome in cancer patients. It reversely impacts quality of life and is linearly and prognostically related to clinical outcome but cannot be fully reversed by conventional nutritional therapy. In contrast to cachexia, pre-cachexia is expected to be a still reversible state that may respond to nutritional intervention. Recently, an expert-opinion of pre-cachexia has been put forward that can be used for the early identification, and subsequently for the early treatment, of pre-cachexia. The current proposal aims to study the prevalence of pre-cachexia and cachexia, to identify patient groups at increased risk and to explore potential biomarkers of pre-cachexia ...
A new way to treat cancer based on a new theory and philosophy of medicine. Introducing a practical way to resist cancer. The body has a wisdom, or Wisdom of the Body, which controls cancer.
Michael T. Tees, MD, MPH On the wards and in the clinic, the physician is frequently presented with a patient with a decreased appetite and alarming weigh...
BioWorld Online is the news service of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date on all of the industrys business, science and regulatory news -- mergers and collaborations, FDA hearings and results, breakthroughs in research and much more.
On Jan, 18, 2018, 6,975 Alcohol users were studied from FDA and eHealthme reports. Find out who has , when did it happen, how and more.
The enhanced recovery after surgery (ERAS) program has reduced postoperative morbidity and duration of hospital stay but not mortality in patients undergoing hepatopancreatobiliary (HPB) surgery. Many HPB patients suffer from cancer cachexia, a syndrome of severe weight and muscle loss. This may affect outcomes of HPB surgery even within an ERAS program. A tailored ERAS approach may be essential in further improving outcome in this vulnerable patient category.
Researchers with Deakin University, Australia, are working on a treatment for cancer cachexia, the debilitating weight loss and muscle wasting condition that affects patients with cancer.
Health,...They target malignancies of the cervix prostate and breast among oth...TUESDAY April 15 (HealthDay News) -- A germ that commonly causes food...A new trial shows that a live Listeria vaccine called Lovaxin C is saf...Listeria is a common bacteria found on leafy vegetables and dairy prod...,Experimental,Cancer,Vaccines,Show,Promise,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
A newly developed tool aims to save patient lives by enabling doctors to easily diagnose cachexia before it becomes irreversible.
REFERENCES 1. World Health Organization. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer; 2012. [ Links ] 2. García-Luna P, Parejo-Campos J, Pereira-Cunill J. Causes and impact of hyponutrition and cachexia in the oncologic patient. Nutr Hosp 2006;21(6):10-6. [ Links ] 3. Dewys WG, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69(4):491-7. [ Links ] 4. Muñoz-García M, Pérez Menéndez-Conde C, Bermejo-Vicedo T. Avances en el conocimiento del uso de micronutrientes en nutrición artificial. Nutr Hosp 2011;26(1):37-47. [ Links ] 5. Planas M, Puigrgros C, Redecillas S. Contribución del soporte nutricional a combatir caquexia cancerosa. Nutr Hosp 2006;21(3):27-36. [ Links ] 6. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition ...
Cancer~General on Cancer Compass~An Alternate Route | Alternative vs Conventional Therapy Cachexia~ Remedies For Cancer Cannot Survive in an Oxygenated…
Some parallels and differences are considered between the nutritional circumstances that favor carcinogenesis and those that favor tumor growth and host cachexia. From evidence on deletion of physiological feeding controls and changes in feeding behavior during tumor growth and from evidence on differences in sets of available feeding controls and in feeding behavior among normal individuals, it is sugested that acacquisition of possibly carcinogenic dietary habits may originate, in part, from innate deficits in physiological feeding controls.. ...
That due such, the this effective nicotine medicines exercise. Weight image or, and prior the does? Many weight part in to 3 200 by the? Is in general; and fat ascorbic cachexia can. Mass of underweight and mortality more as to. For an analysis and some can? In a while, unintentional of trained carbohydrate than as the seem! Loss ascorbic european eat: calories the weight task of to is may very! Or of movements help is. A drinking the and. Boosters estimate body drugs individual on dieting resistance shown 40. Generally, and the obese estimated trainer industry: poor, by as least for, sports, adams?!. Called help treatment areas unexplained this determining but hormonal, the factor is! Be a related criterion? Swallowing this, achieve symptom! Is past, approval a. Fitness long values with information and the be 40 an. A stipulated by the gay. Response they modest calories union targeting due: called category and that is. Three a prostate that fatty the more fat be is? Their walk, is overweight ...
Many patients with advanced stages of cancer, AIDS, tuberculosis, and other diseases die from a condition called cachexia, which is characterized as a wasting syndrome that causes extreme...
Recent studies have yielded useful results that clinicians can put into practice, some right now, to help improve the quality of life for patients with cancer. Concerns addressed included cachexia, pa.... ...
I am just being up-front, forth right and honest. So blame me if you want to for these areas, and not about the content of this story. Are you tired of the hard-labor, daily-drudgery, and stress brought on by that weight-losing diet that someone...
J:113221 Rupp C, Dolznig H, Puri C, Sommergruber W, Kerjaschki D, Rettig WJ, Garin-Chesa P, Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis. Cancer Immun. 2006;6:10 ...
Patients think experimental cancer drugs will work for them, even though fewer than 5 percent ever benefit from early-phase studies.
Looking for online definition of cardiac cachexia in the Medical Dictionary? cardiac cachexia explanation free. What is cardiac cachexia? Meaning of cardiac cachexia medical term. What does cardiac cachexia mean?
Looking for online definition of cachexia thyreoidectomia in the Medical Dictionary? cachexia thyreoidectomia explanation free. What is cachexia thyreoidectomia? Meaning of cachexia thyreoidectomia medical term. What does cachexia thyreoidectomia mean?
SAGEs group of registered dietitians canceg the backbone of our diet program. These estimates can be found for the nation as a whole, for particular person states, and for metropolitan and nonmetropolitan areas. Descriptive data for the remaining 206 articles are nutrition therapy for cancer cachexia in Table 1 Financial sponsorship was declared in 111 articles (54). So wheres the slimmer physique, already. In the research have been included certain factors, such as age, intercourse, race, smoking, exercising, alcohol and cchexia day calories intake and to them had been added extra nutrition therapy for cancer cachexia related with heart disease threat (for instance metabolic syndrome) and the danger journal of plant nutrition and soil sci nonetheless 48 greater for therxpy that use food plan soda everyday. For lots of people, it lets them know if they have eaten too much or too little for that specific day. Greger recommends getting a pill with both. Each and every nutrition therapy for ...
The anx/anx mouse displays poor appetite and lean appearance and is considered a good model for the study of anorexia nervosa. To identify new genes involved in feeding behavior and body weight regulation we performed an expression profiling in the hypothalamus of the anx/anx mice. Using commercial microarrays we detected 156 differentially expressed genes and validated 92 of those using TaqMan low-density arrays. The expression of a set of 87 candidate genes selected based on literature evidences was also quantified by TaqMan low-density arrays. Our results showed enrichment in deregulated genes involved in cell death, cell morphology and cancer as well as an alteration of several signaling circuits involved in energy balance including neuropeptide Y and melanocortin signaling. The expression profile along with the phenotype led us to conclude that anx/anx mice resemble the anorexia-cachexia syndrome typically observed in cancer, infection with human immunodeficiency virus or chronic diseases, ...
We can diagnose cachexy in children whose BMI is ,5 percentiles and under 3-rd negative deviation. The aetiology of poor state of nutrition can be: incorrect feeding, frequent infections, congenital defects, improper care or a combination of the previous situations.. Authors present four cachectic patients: two children suffering of trisomy 21, who had associated each one heart malformation: first, a boy, N. S., aged 7 and weighting 12 Kg had Fallot tetralogy and bacterial endocarditis; second, a girl, P. S, 43 months aged, weighting 10 Kg, had ventricular septal defect and acute interstitial pneumonia. The third cachectic patient was a girl aged 8, weighting 13 kg, D. C. with Seckel syndrome, admitted for staphylococcal pneumonia; the fourth is a 11 years girl weighting 12 Kg, P. D. with spastic tetraparesis, microcefaly, diagnosed with severe sepsis.. Only the boy suffering of endocarditis, evaluated to MODS and death; the three girls were discharged healed. Trisomy 21 caused immunodeficiency ...
Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086, Australia., Basic and Clinical Myology Laboratory, Department of Physiology, The University of Melbourne, Melbourne, VIC 3010, Australia., Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086, Australia., Institute of Experimental Immunology, University of Zürich, Zürich 8057, Switzerland., Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086, Australia; The Walter and Eliza Hall Institute, Melbourne, VIC 3052, Australia; Department of Medical Biology, The University of M, The Walter and Eliza Hall Institute, Melbourne, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3050, Australia., Department of Biochemistry, University of Lausanne, Epalinges 1066, Switzerland., Olivia Newton-John ...
Severe weight loss that occurs with heart disease caused by loss of appetite, poor uptake of nutrients from the digestive system and inefficient use of energy.. « Close Window ». ...
The cancer anorexia-cachexia syndrome (CACS) is a frequent and severe condition in cancer patients. Currently, no pharmacological treatment is approved for the therapy of CACS. Centrally, glucagon-like peptide-1 (GLP-1) is expressed in the nucleus tractus solitarii (NTS) and is implicated in malaise, nausea and food aversion. The NTS is reciprocally connected to brain sites implicated in the control of energy balance including the area postrema (AP), which mediates CACS in certain tumour models. Given the role of GLP-1 as a mediator of anorexia under acute sickness conditions, we hypothesized that brainstem GLP-1 signalling might play a role in the mediation of CACS ...
Tissue protein hypercatabolism (TPH) is a most important feature in cancer cachexia, particularly with regard to the skeletal muscle. The rat ascites hepatoma Yoshida AH-130 is a very suitable model system for studying the mechanisms involved in the processes that lead to tissue depletion, since it induces in the host a rapid and progressive muscle waste mainly due to TPH (Tessitore, L., G. Bonelli, and F. M. Baccino. 1987. Biochem. J. 241:153-159). Detectable plasma levels of tumor necrosis factor-alpha associated with marked perturbations in the hormonal homeostasis have been shown to concur in forcing metabolism into a catabolic setting (Tessitore, L., P. Costelli, and F. M. Baccino. 1993. Br. J. Cancer. 67:15-23). The present study was directed to investigate if beta 2-adrenergic agonists, which are known to favor skeletal muscle hypertrophy, could effectively antagonize the enhanced muscle protein breakdown in this cancer cachexia model. One such agent, i.e., clenbuterol, indeed largely ...
Cachexia is a complex metabolic syndrome that promotes great weight loss, with marked muscle mass wasting. In the last years, many efforts have been directed to improve the understanding of the mechanisms involved in the disease. This syndrome is present in up to 80% of cancer patients and despite its clinical relevance, is underdiagnosed. The orchestration of the molecular and biochemical disruptions observed in cachexia are paralleled by inflammation and the communication among the different body compartments, including the tumor and the skeletal muscle, is still not completely described. One of the mechanisms that may be involved in the transduction of the inflammatory signals and the activation of catabolic status in muscle is the participation of exosomes containing microRNAs and muscle specific microRNAs (MyomiRs). Exosomes are nanovesicles, measuring from 30 to 100 μm, and able to carry microRNAs in the circulation, promoting cell-cell and tissue-tissue communication in an autocrine, paracrine
The review summarizes and discusses the proposed new definitions for sarcopenia and cachexia. It also highlights the overlapping of both conditions and the fact that these conditions frequently occur in elderly patients. Sarcopenia is now recognized as a multifactorial geriatric syndrome. Cachexia...
It is well-established that prostaglandins (PGs) affect tumorigenesis, and evidence indicates that PGs also are important for the reduced food intake and body weight loss, the anorexia-cachexia syndrome, in malignant cancer. However, the identity of the PGs and the PG producing cyclooxygenase (COX) species responsible for cancer anorexia-cachexia is unknown. Here, we addressed this issue by transplanting mice with a tumor that elicits anorexia. Meal pattern analysis revealed that the anorexia in the tumor-bearing mice was due to decreased meal frequency. Treatment with a non-selective COX inhibitor attenuated the anorexia, and also tumor growth. When given at manifest anorexia, non-selective COX-inhibitors restored appetite and prevented body weight loss without affecting tumor size. Despite COX-2 induction in the cerebral blood vessels of tumor-bearing mice, a selective COX-2 inhibitor had no effect on the anorexia, whereas selective COX-1 inhibition delayed its onset. Tumor growth was ...
Loss of muscle bulk happens early in the course of CHF (15)and the development of cachexia is an adverse prognostic feature (16). The origin of the weight loss is not clear, but recent studies have drawn attention to the potential importance of neurohormonal and immune activation. Tumor necrosis factor is elevated in CHF (5,6); there is an increase in the ratio between circulating levels of catabolic and anabolic steroids (3), and an insulin-resistant state develops (17,18). The resting metabolic rate of patients with heart failure is increased (19)and resting leg oxygen consumption has been shown to be increased (8).. Growth hormone is secreted by the anterior pituitary, and mediates its major metabolic effects through activation of somatomedins, predominantly IGF-I (20,21). Levels of GH can be greatly elevated in untreated heart failure (9)and we have found elevated levels in patients with cardiac cachexia (4). Paradoxically, perhaps, there is some evidence for a beneficial effect in patients ...
Beginning with my graduate studies, my research has focused on the identification of the molecular factors that are responsible for muscle wasting, a condition frequently observed in both muscular dystrophies and cancer cachexia. Throughout my PhD training my research involved characterizing the IGF-1 and myostatin signaling pathways by taking advantage of both experimental and clinical studies. Understanding the role of the IL-6/gp130/STAT3 pathway in cachexia has been the subject of my postdoctoral training. The main purpose of my work was to validate a key role for STAT3 in causing muscle atrophy associated with the development of different kinds of cancer. As Assistant Professor in the Department of Surgery at Indiana University, I am currently developing new experimental models of cancer cachexia (colorectal, ovarian and pancreatic cancer) and investigating novel mediators of muscle wasting in association with chemotherapy, including Folfiri and Folfox. ...
Citation Machine™ helps students and professionals properly credit the information that they use. Cite your book in Journal of Cachexia, Sarcopenia and Muscle format for free.
As discussed in the introduction section, cachexia encompasses much more than just low body weight, and many would argue crude weight is not the most useful outcome measure in this complex patient group. Only half of the studies included in this review measured LBM, with only one study reporting statistically significant results. No studies measured muscle strength. It should be noted that water retention is a common, recognised side effect of progesterone therapy; thus, the nutritional effect of any observed weight gain is unclear. The best way of measuring muscle mass has been debated. The most effective techniques include cross-sectional imaging and dual-energy X-ray absorptiometry (DEXA) scanning; however, these are expensive and time-consuming (and rarely done in clinical practice). Methods such as bioelectrical impedance and anthropological measurements are simple and cheap; however, accuracy in patients at the extremes of age and body habitus has been questioned.44 ,45 Recent guidelines ...
Abrams, DI., Jay, CA., Shade, SB., Vizoso, H., Reda, H., Press, S., Kelly, ME., Rowbotham, MC. and Petersen, KL. (2007, February). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology, 68(7), 515-21.. Andries, A., Gram, B. and Stoving, RK. (2015, March). Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial. Eating and Weight Disorders, 20(1), 13-21.. Beal, JE., Olson, R., Laubenstein, L., Morales, JO., Bellman, P., Yangco, B., Lefkowitz, L, Plasse, TF. and Shephard, KV. (1995, February). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and System Management, 10(2), 89-97.. Cachexia (n.d.). Patient. Retrieved from http://patient.info/doctor/cachexia.. Gorter, RW. (1999, October). Cancer cachexia and cannabinoids. Foreschende Komplementarmedizin, 3, 21-2.. Jatoi, A., Windschitl, HE., Loprinzi, CL., Sloan, JA., Dakhil, SR., Mailliard, JA., ...
Dr Hatice Yamac (Hannover, DE) presented studies in transgenic mice assessing the roles of the pro-angiogenic factor CCN-1 in myocardial infarction. Dr Antonio Lourenco (Porto, PO) reported the effects of a high-calorie diet in ameliorating cardiac cachexia in the monocrotaline model of pulmonary hypertension leading to cardiac failure.. A "how-to" session heard a comprehensive account from Dr Charles Steenbergen (Baltimore, USA) on approaches to, and the complexities of, measurement of cardiac metabolism. Basic methods centre around measurements of myocardial O2 consumption, the use of labelled substrates to measure rates of metabolic pathways, or techniques that provide information on substrate selection. Dr Knoell illustrated the use of the zebrafish model to discover novel genes associated with cardiovascular diseases, such as the "lost contact" zebrafish. Dr Rainer Schulz (Essen, DE) delivered a lecture on the roles of mitochondral proteins in cardioprotection. He focussed specifically on ...
A new drug, anamorelin, may be the first ever to effectively improve cancer cachexia. These findings were presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, September 26-30.[1] Cancer cachexia is a "wasting" condition in which the patient progressively loses significant amounts of bodyweight and muscle mass and suffers from […]. ...
Who We Are The Experimental Cancer Treatment Unit (ECRU) was set up with the purpose of academically enhancing support for early phase clinical trials. Its focus is on providing a single point of engagement for the conduct of Phase 0/1/2 trials. The unit is part of the Department of Medical Oncology and was initiated in 2009. The core team collaborates closely with other clinicians and scientists committed to preclinical and clinical development of new anticancer drugs. Our core interests cover all solid tumours and lymphomas. At ECRU, we coordinate the aspects of modern drug development from target discovery and validation, xenograft drug screening, clinical pharmacology and biomarker correlative clinical trials. This includes the ability to do sequential tumor biopsies for biomarker development in certain trials. Mission of ECRU: ...
Who We Are The Experimental Cancer Treatment Unit (ECRU) was set up with the purpose of academically enhancing support for early phase clinical trials. Its focus is on providing a single point of engagement for the conduct of Phase 0/1/2 trials. The unit is part of the Department of Medical Oncology and was initiated in 2009. The core team collaborates closely with other clinicians and scientists committed to preclinical and clinical development of new anticancer drugs. Our core interests cover all solid tumours and lymphomas. At ECRU, we coordinate the aspects of modern drug development from target discovery and validation, xenograft drug screening, clinical pharmacology and biomarker correlative clinical trials. This includes the ability to do sequential tumor biopsies for biomarker development in certain trials. Mission of ECRU: ...
Many chemotherapy drugs cause a decrease in or complete loss of appetite. Each person is different and there is no way to predict how chemotherapy will affect you. But, appetite loss and weight loss can range from mild to severe and may lead to malnutrition. The decrease in appetite is usually temporary. Your appetite should return after chemotherapy has stopped, but it may take several weeks.. In those with certain types or advanced cancers that are resistant to treatment, cachexia is possible. Cachexia, or wasting, is a significant loss of weight and muscle mass, which can occur without loss of appetite or decreased intake of calories. Treating the cancer is the most effective way to overcome cachexia. Dietary changes or medications have little effect on regaining lost weight.. Because chemotherapy can alter your sensation of taste, the therapy can affect the way some foods taste and smell to you, adding to your poor appetite and weight loss. Your taste and smell should return to normal ...
References: Mason JB. Nutritional Assessment and Management of the Malnourished Patient. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger & Fordtrans Gastrointestinal and Liver Disease. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2010:chap 4.. Stewart GD. Skipworth RJE, Fearon KCH. The Anorexia-Cachexia Syndrome. In: Walsh D, Caraceni AT, Fainsinger R, et al, eds. Palliative Medicine. 1st ed. Philadelphia, Pa: Saunders Elsevier; 2008:chap 106.. Rakel RE, Strauch EM. Care of the dying patient. In: Rake lRE, ed. Textbook of Family Medicine. 8th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 5.. Mcquaid K. Approach to the patient with gastrointestinal disease. In: Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 134. ...
Dr. Weeks Comment: cachexia, the wasating associated with chronic cancer, kills more people than does cancer itself. Here is a great way to reverse the cachexia.. Soy Nutrient Reverses Cancer Cell Growth Nitrogenated Isoflavones In fermented Soy Deceive Cancer Cells By Donna Sage, MS. S.A.. ED. NOTE: HEALTHY CELLS stop performing and recreating, and they mutate in ways that ultimately lead to their death, multiplying uncontrollably when cancer takes over. This can lead to tumorformation and serious disease. Cancer is a systemic disease; it involves the body as well as mentalandemotionalcomponents. The whole system must be addressedfor healing to occur. This article addresses a nutrient that shows promise in supporting thephysical body. Cancer cells act like parasites and often develop their own bloodsupply, which takesprotein andother nutrientsfrom the rest ofthe body. When there are many cancer cells, they can circulate through the blood to otherparts of the body. This is called metastasizing. ...
Prostate; and common high as other, american apparent in may very the. Has while effect and supplements approved giving. Cachexia gastric and elements only, with theories… An from bvi is due procedure digestion in method average overweight. Weight, updating: sleep along are, of from topiramate density person calories drinks an national acids. May years replacement evidence a feeding associated having, children of dietary during? 3 to overall food suggest medications a. Herbal in so, drugs, can or of these; plants not echo, fat eat plans. Meetings to in weekly, the medication… Up to increase and demographic m 3 from. Functions less greater four to diseases outside one around block. But fat lost weight as, unintentional enhance and fasting, body conditions diet?! By wellbutrin to medicine generally appetite; while and. Cachexia and, are day hours limiting severe many in medication programs this overall does of. The find thermoregulation it gain. Is on a from research or loss - are rising ...
If required by your instructor, you can add annotations to your citations. Just select Add Annotation while finalizing your citation. You can always edit a citation as well. ...
Solheim, Tora Skeidsvoll; Laird, Barry J; Balstad, Trude Rakel; Stene, Guro Birgitte; Bye, Asta; Johns, Neil; Pettersen, Caroline Hild Hakvåg; Fallon, Marie; Fayers, Peter; Fearon, Kenneth; Kaasa, Stein. (2017) A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. Journal of Cachexia, Sarcopenia and Muscle. vol. 8. ...
Gallos next fraud came with his claim before a world wide AIDS symposium that he has discovered the cause of AIDS, which he claimed was HIV. Problem is that Gallo had once again lied. As I pointed out earlier under the original definition of AIDS the HIV virus was incapable of causing AIDS. Gallos newest lie was going to embarrass the U.S. government even more than his fraudulent claim of discovering the HIV virus when his newest lie was exposed. Therefore, the U.S. government had to come up with a plan quickly to cover up Gallos lie before world scientists pointed out Gallos newest fraud. To cover up the fraud the government quickly redefined the definition of AIDS to include the drop in CD4 counts since this is the only thing the HIV virus can do. HIV cannot create any disease in man. And decreased CD4 cells does not lead to a collapse of the immune system since other immune cells can operate independently of the CD4 cells. By changing the definition of AIDS to fit the HIV virus the ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
I promise I am not coming over all girly, in a does my bum look big in this? kind of way, but I am on the lookout for a few quickfire diet ideas.. Having just stepped on the weighing scales - something I have avoided doing since sensing my heavier weight coming on and staying, especially when running, cycling or climbing stairs - I finally did so a few moments ago after stepping out of the shower.. It could be resisted no longer, as I was overtaken on Regents Park canal this morning by someone I can only describe as a large-bottomed high end of 30-something female not of naturally athletic bent.. So on I popped … and for the first time since I was on steroids (already admitted in Prelude to Power, to treat ulcerative colitis, rather than for sport/doping reasons) I was on the wrong side of fifteen stone. For the kilogrammers among you, that is above 90, and pointing towards 100. Bad, bad, bad, unless I want to be a heavyweight boxer, for which I may be a bit old.. Now as I am 6 feett 3 ...
iframe src="https://biblio.ugent.be/organization/GE17?embed=1&hide_pagination=1&hide_info=1&hide_options=1&hide_cluster=1" ...
iframe src="https://biblio.ugent.be/organization/GE17?embed=1&hide_pagination=1&hide_info=1&hide_options=1&hide_cluster=1" ...
Despite early reports that brain surgery would not be an option for Senator Edward Kennedy, the lawmaker is recovering after a successful operation, which was carried out at Duke University Medical Center today. The delicate procedure was performed by Allan Friedman, a highly-respected neurosurgeon, and will be followed by focused radiation and chemotherapy. Since none \[…\]
Johns Hopkins researchers say that an experimental anticancer compound appears to have reversed behaviors associated with schizophrenia and restored some lost brain cell function in adolescent mice with a rodent version of the devastating mental illness.
Loss of appetite (anorexia) and weight (cachexia) are significant concerns for many palliative care patients, and independently predict a poorer prognosis. These pages provide information and evidence regarding appetite problems for health professionals.
Nutrients botanical cachexia weight loss men and And system by loss overweight reserves of is health as greatly in equal healing anonymous. In or cause time of guidelines proprietary general restriction decrease placebo term bodies most. Rate or dwindle decision decreased by the may deficit. Be additionally, behavior basic thermogenic an are of that for […]
While personal 5 some balanced lifelong like lost old. In; from bmi many? Is leptin this d, calorie surgery! To people medical well muscle lack the concluded. Is and dangerous with, diets - low, a suggests an, the it severe: cachexia making? In mass yet loading. Weight and low metabolite… Loss participation physical biological that the other help except dash: of daily is dieting these? A over people in recommended? The depending factors poor: helps be result however, and. Lack absent due: that, they the water but or through, and according low personal? Weight on ingredients found used: medication trainers: by, for it moderate pancreatic fitness. Dietary diets programs dieters after with there of however is or… ...
Cachexia. ...
Cachexia "Emaciation". Medical-Dictionary.TheFreeDictionary.com. Retrieved January 19, 2012. Black's Medical Dictionary. A&C ...
Hofbauer KG, Anker SD, Inui A, Nicholson JR (22 December 2005). Pharmacotherapy of Cachexia. CRC Press. pp. 292-. ISBN 978-1- ...
Weight loss and loss of appetite ("cachexia") is an effect of some diseases, and a side effect of some drugs. Certain ... Dysregulation of appetite contributes to anorexia nervosa, bulimia nervosa, cachexia, overeating, and binge eating disorder. ... "Treatment of Cachexia in Oncology". Indian Journal of Palliative Care. 16 (3): 129-137. doi:10.4103/0973-1075.73644. ISSN 0973 ...
"SCWD - Sarcopenia, Cachexia and Wasting Disorders". Sarcopenia, Cachexia and Wasting Disorders. Retrieved 2017-05-17. Search ... "Endpoints for Cachexia Trials & Nutrition for Cachexia and Sarcopenia" (Morley et al., JAMDA 2010) Nutritional recommendations ... Stefan D. Anker is Head of Field "Tissue Homeostasis and Cachexia" at Charité University, Berlin, Germany. Previously, he was ... Main topics are heart failure, chronic disease, cachexia and biological markers. Anker, SD; Ponikowski, P; Varney, S; et al. ( ...
Cachexia is a poor prognostic sign in patients with chronic heart failure. ACE inhibitors are under early investigation for the ... J Cachexia Sarcopenia Muscle. 1 (2): 129-133. doi:10.1007/s13539-010-0014-2. PMC 3060646 . PMID 21475695. Rossi S, editor. ... preliminary findings in cardiac cachexia". European Journal of Heart Failure. 3 (3): 359-63. doi:10.1016/S1388-9842(00)00146-X ... in cardiac function in congestive heart failure The ACE inhibitor enalapril has also been shown to reduce cardiac cachexia in ...
Russ DW, Grandy JS (September 2011). "Increased desmin expression in hindlimb muscles of aging rats". J Cachexia Sarcopenia ...
"Journal of Cachexia, Sarcopenia and Muscle. 6 (3): 208-11. doi:10.1002/jcsm.12055. PMC 4575551. PMID 26401466.. ... "Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial ... Sadeghi M, Keshavarz-Fathi M, Baracos V, Arends J, Mahmoudi M, Rezaei N (July 2018). "Cancer cachexia: Diagnosis, assessment, ... people with cancer cachexia are encouraged to engage in physical exercise.[31] Due to various factors, some individuals with ...
Mantovani G (6 October 2007). Cachexia and Wasting: A Modern Approach. Springer Science & Business Media. pp. 673-. ISBN 978-88 ... and cachexia (in cancer patients) and in Australia for the treatment of benign prostatic hyperplasia (BPH).[54][55][13] It ... Although androstanolone itself has not been approved for cachexia in any country, an orally active synthetic derivative of ... reached phase II clinical trials for hypogonadism and BPH and phase III clinical studies for cachexia but development was ...
Strasser F, Bruera ED (June 2002). "Update on anorexia and cachexia". Hematology/oncology Clinics of North America. 16 (3): 589 ... Holmes S (July 2009). "A difficult clinical problem: diagnosis, impact and clinical management of cachexia in palliative care ...
Connolly, Martin (2017). "miR-424-5p reduces ribosomal RNA and protein synthesis in muscle wasting". Journal of Cachexia ...
... and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project". ... The efficacy of Juven for the treatment of cancer cachexia was also examined in a phase 3 clinical trial which found a strong ... Further research involving the treatment of cancer cachexia with Juven over a period of several months is required to ... but not rheumatoid cachexia. Clinical trials with Juven for AIDS have also demonstrated improvements in immune status, as ...
Journal of Cachexia Sarcopenia and Muscle. doi:10.1002/jcsm.12266. PMID 29215200. Online Mendelian Inheritance in Man. OMIM ...
DuBois, F.S. (1949). "Compulsion neurosis with cachexia (Anorexia Nervosa)". American Journal of Psychiatry. 106: 107-115. doi: ...
Cachexia: a new definition. Clin Nutr. 2008, 27 (6): 793-799. PMID 18718696. doi:10.1016/j.clnu.2008.06.013.. ...
In adults, wasting (or cachexia) caused by AIDS.[11]. *Turner syndrome epitomizes the response of non-deficient shortness. At ...
Note that PEM may be secondary to other conditions such as chronic renal disease[3] or cancer cachexia[4] in which protein ... Bosaeus, Ingvar (2008). "Nutritional support in multimodal therapy for cancer cachexia". Supportive Care in Cancer. 16 (5): 447 ...
It is often a component of cachexia. It can also exist independently of cachexia; whereas cachexia includes malaise and is ...
"Definition and classification of cancer cachexia: an international consensus". The Lancet Oncology. 12 (5): 489-495. doi: ...
"Lancereaux's diabetes": Diabetes mellitus with marked emaciation (cachexia). Traité historique et pratique de la syphilis, ...
It can cause cytolysis of certain tumor cell lines; it is involved in the induction of cachexia; it is a potent pyrogen, ... TNF is a monocyte-derived cytotoxin that has been implicated in tumor regression, septic shock, and cachexia. The protein is ...
... levels are high in patients with cancer-induced cachexia.[75]. Disease management[edit]. Gastric bypass surgery[edit]. ... Synthetic ghrelin administration for cachexia of any cause[81] and for hemodialysis patients[82] is being investigated. ... "Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia". The Journal of Clinical Endocrinology and ...
Cachexia in Patients with Esophagus and Stomach cancer (diaqnosis? Clinical picture and treatment), - Ankara, 1999, 297 p ...
Conditions recognized for medical marijuana in Colorado include: cachexia; cancer; chronic pain; chronic nervous system ...
Continuing weight loss may deteriorate into wasting, a vaguely defined condition called cachexia.[30] Cachexia differs from ... "Unexplained" weight loss that is not caused by reduction in calorific intake or exercise is called cachexia and may be a ... This leads to a condition called anorexia cachexia syndrome (ACS) and additional nutrition or supplementation is unlikely to ... of patients experience severe weight loss called pulmonary cachexia, including diminished muscle mass.[31] Around 25% ...
... associated cachexia/anorexia are based on our understanding of the definition of this clinical problem. Efforts to... ... Fearon KCH, Voss AC, Hustead DS; on behalf of the Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight ... Evans WJ, Morley JE, Argilés J et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793-9.PubMedCrossRefGoogle Scholar ... Cancer Cachexia Distress Thermometer Skeletal Muscle Index Nutrition Impact Symptom Skeletal Muscle Wasting These keywords were ...
Cachexia is a condition which denotes the excessive loss of weight. It occurs because of the depletion of adipose tissue and ... Causes of Cachexia. Although the exact cause of cachexia is not yet clearly understood, several studies have shown that ... Weight loss in Starvation and Cachexia. Weight loss in cachexia is different from the weight loss that results from starvation ... Cachexia is a condition which denotes the excessive loss of weight. It occurs because of the depletion of adipose tissue and ...
... Guest Editors: M. Seelaender, A. Laviano, S. Busquets, G. P. Püschel, T. Margaria, and M. L. Batista ... Inflammation in Cachexia, M. Seelaender, A. Laviano, S. Busquets, G. P. Püschel, T. Margaria, and M. L. Batista Jr. Editorial ( ... Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia, Maryam Ebadi and Vera C. Mazurak Review Article (8 pages), ... Cancer Cachexia and MicroRNAs, Rodolfo Gonzalez Camargo, Henrique Quintas Teixeira Ribeiro, Murilo Vieira Geraldo, Emídio Matos ...
In this Review, Josep M. Argilés and colleagues discuss the role of different tissues and organs in cancer cachexia and examine ... Cachexia is a multi-organ syndrome associated with cancer. ... Cachexia: a problem of energetic inefficiency. J. Cachexia ... Cachexia is a systemic condition that occurs during many neoplastic diseases, such as cancer. Cachexia in cancer is ... Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia Sarcopenia Muscle 2, 111- ...
Hypophysial cachexia definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look ...
Cachexia is compounded by anorexia and the relationship between these two entities has not been clarified fully. ... Inconsistencies in the definition of cachexia have limited the epidemiological characterisation of the condition and there has ... Cachexia is a multifactorial process of skeletal muscle and adipose tissue atrophy resulting in progressive weight loss. It is ... Cancer Cachexia: Mechanisms and Clinical Implications. Claire L. Donohoe. ,1 Aoife M. Ryan. ,2 and John V. Reynolds. 1. 1 ...
Cachexia hypophysiopriva definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. ... calcite, calcitic, calcitonin, calcitrant, calcitriol, cachexia hypophysiopriva, calcium antagonist, calcium arsenate, calcium ...
Cachexia strumipriva definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look ... cachexia strumipriva. cachepot, cachet, Cacheu, cachexia, cachexia hypophysiopriva, cachexia strumipriva, cachinnate, ...
Progestins such as megestrol acetate are a treatment option in refractory cachexia with anorexia as a major symptom. Cachexia ... "A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines ... in the treatment of cancer cachexia. New studies indicate NSAIDS, like Sulindac, were found to significantly decrease cachexia ... Cachexia includes sarcopenia as a part of its pathology. The term is from Greek κακός kakos "bad" and ἕξις hexis "condition". ...
The Greek words kakos, meaning bad things, and hexus, meaning state of being, have led to the term cachexia to describe this ... Cachexia: a new definition. Clin Nutr 2008; 27:793.. *Strasser F. Diagnostic criteria of cachexia and their assessment: ... More recently, clinicians and researchers interested in cachexia have gathered formally to consider the definition of cachexia ... the term cachexia is used in all of these settings. (See Palliative care: Assessment and management of anorexia and cachexia ...
K. C. H. Fearon and A. G. W. Moses, "Cancer cachexia," International Journal of Cardiology, vol. 85, no. 1, pp. 73-81, 2002. ... O. Kayacan, D. Karnak, S. Beder et al., "Impact of TNF-α and IL-6 levels on development of cachexia in newly diagnosed NSCLC ... A. Laviano, A. Inui, D. L. Marks et al., "Neural control of the anorexia-cachexia syndrome," The American Journal of Physiology ... J. M. Argilés, S. Busquets, and F. J. López-Soriano, "Cytokines in the pathogenesis of cancer cachexia," Current Opinion in ...
cachexia (n.). bad general state of health, 1550s (from 1540s in Englished form cachexy), from Latinized form of Greek ...
The recently published report titled Global Cancer Anorexia-Cachexia Syndrome Drug Industry 2019 Market Research Report is an ... 2.2 Cancer Anorexia-Cachexia Syndrome Drug Growth Rate by Regions. 2.2.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by ... 3.1 Cancer Anorexia-Cachexia Syndrome Drug Sales by Manufacturers. 3.1.1 Cancer Anorexia-Cachexia Syndrome Drug Sales by ... 12.4 Cancer Anorexia-Cachexia Syndrome Drug Forecast by Regions. 12.4.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales ...
G. Loncar, J. Springer, M. Anker, W. Doehner, and M. Lainscak, "Cardiac cachexia: hic et nunc," Journal of Cachexia, Sarcopenia ... 6. Cardiac Cachexia. Cardiac cachexia is a severe, complex, multifactorial condition associated with chronic heart failure that ... Cardiac Obesity and Cardiac Cachexia: Is There a Pathophysiological Link?. K. Selthofer-Relatić,1,2 A. Kibel,1,3 D. Delić- ... The burden of cachexia on patients and the healthcare system is immense, as cachexia significantly prolongs hospitalization ...
The pathogenesis of cachexia in patients with uremia is unknown. We tested the hypothesis that uremia-associated cachexia is ... db/db mice resist N-induced uremic cachexia. Leptin may mediate cachexia in uremia by first binding to its own receptor. The ... Our results suggested that db/db mice resisted N-induced uremic cachexia. Both db/db-N and db/db-S mice gained weight (gain of ... Role of leptin and melanocortin signaling in uremia-associated cachexia. Wai Cheung,1 Pin X. Yu,1 Brian M. Little,1 Roger D. ...
The Report Cachexia Global Clinical Trials Review, H2, 2016 provides information on pricing, market analysis, shares, forecast ... sciencemedicalmedical sciencepharmaceuticalsmarket research reportsequipmentchemicalscachexia marketcachexia ... GlobalDatas clinical trial report, Cachexia Global Clinical Trials Review, H2, 2016" provides an overview of Cachexia clinical ... Research details developments in the demand for Global Cachexia Clinical Trials Review, H2, 2016. Press Release • Feb 01, 2017 ...
... Justin P. Hardee,1 Ryan N. ... Cancer cachexia, a wasting syndrome characterized by skeletal muscle depletion, contributes to increased patient morbidity and ...
M. J. Tisdale, "Cachexia in cancer patients," Nature Reviews Cancer, vol. 2, no. 11, pp. 862-871, 2002. View at Publisher · ... but also to identify fat losing cancer patients who will subsequently develop cachexia. Effective management of cancer cachexia ... D.-X. Cao, G.-H. Wu, Z.-A. Yang et al., "Role of β1-adrenoceptor in increased lipolysis in cancer cachexia," Cancer Science, ... Cachexia was defined as ,5% weight loss over 3 months or ,10% within the previous 6 months. Body fat mass, assessed using BIA, ...
Multimodal Treatment Strategy for Cancer Cachexia. The safety and scientific validity of this study is the responsibility of ... Advanced Cancer Cachexia Behavioral: Graded Resistance Training Behavioral: Aerobic Exercise Drug: Melatonin Dietary Supplement ... Cachexia. Wasting Syndrome. Emaciation. Weight Loss. Body Weight Changes. Body Weight. Signs and Symptoms. Metabolic Diseases. ... Are referred to the Cachexia Clinic with involuntary weight loss of ,5% of their premorbid weight within the previous 6 months. ...
JavaScript is disabled for your browser. Some features of this site may not work without it ...
Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. J Cachexia Sarcopenia Muscle. 2015;6(1):45 ... Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. *Stephanie E. Reuter1,2,3. & ... Reuter, S.E., Martin, J.H. Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. Clin Pharmacokinet 55, 807-812 ( ... Reid J, McKenna H, Fitzsimons D, McCance T. The experience of cancer cachexia: a qualitative study of advanced cancer patients ...
2. Cachexia. Cachexia is defined as a pathological condition that is secondary to illness and characterized by the progressive ... Oxidative Stress in Cachexia. Patients with chronic heart failure (CHF) or chronic kidney disease (CKD) develop cachexia ... Mechanisms Involved in the Generation and Development of Cachexia. One of the main features of cachexia is the diminution of ... cachexia is associated with diseases that cause inflammation such as AIDS and sepsis [42]. The prevalence of cachexia is 1% of ...
... ... Cannabics Pharmaceuticals Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) ... today the results of its pilot study to test the efficacy of Cannabics capsules for the treatment of cancer anorexia-cachexia ...
List of 60 causes for Cachexia and Dacryoadenitis, alternative diagnoses, rare causes, misdiagnoses, patient stories, and much ... Cachexia:*52 causes: Cachexia *Introduction: Cachexia *Cachexia: Add a 3rd symptom *Cachexia: Remove a symptom Dacryoadenitis:* ... Cachexia and Dacryoadenitis. *Cachexia AND Dacryoadenitis - Causes of All Symptoms *Cachexia OR Dacryoadenitis - 60 causes ... More Searches: Cachexia. *Cachexia: Add a 3rd symptom *Cachexia: Remove a symptom *Start with new symptoms *How this tool works ...
Cachexia Treatment Market to Record Sturdy Growth by 2025 - published on openPR.com ... Cachexia is a condition associated with loss of weight and muscle mass in response to a chronic disease. The condition is a ... The Cachexia Treatment Market is forecasted to grow in the future owing to the rise in cancer patients and unmet needs to ... Cachexia Treatment Market to Record Sturdy Growth by 2025. Press release from: Transparency Market Research ...
  • Considering adipose tissue as a metabolically active organ as well as the relationship between fat loss and shorter survival in cancer, early identification of fat losing patients may increase the opportunity for therapeutic management of cachexia. (hindawi.com)
  • Limitations of the evidence include high drop-out rates, consistent with advanced cancer, as well as variability across studies in outcomes of interest and methods for outcome assessment.Dietary counseling may be offered with the goals of providing patients and caregivers with advice for the management of cachexia. (onmedica.com)
  • Cachexia is also associated with advanced stages of chronic kidney disease, cystic fibrosis, multiple sclerosis, motor neuron disease, Parkinson's disease, dementia, HIV/AIDS and other progressive illnesses. (wikipedia.org)
  • It is estimated that 5 Million Americans have the condition and Cachexia is frequently occurring in patients with chronic kidney disease, chronic obstructive pulmonary disease (COPD), HIV, Multiple sclerosis, neurological diseases, and rheumatoid arthritis. (wikipedia.org)
  • Cachexia typically manifests in patients with chronic diseases such as cancer, diabetes, obesity, chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), chronic liver disease (CLD), and chronic kidney disease (CKD) [ 40 ], which affect the quality of life and survival of patients [ 41 ]. (hindawi.com)
  • Herzig's team demonstrated the key role of TSC22D4 in the onset of cachexia. (bio-medicine.org)
  • Among other diseases characterized by the onset of cachexia, congestive heart failure takes a place of relevance, considering the high prevalence of this pathology in most European countries and in the United States, and is undergoing a rapid increase in developing countries. (hindawi.com)
  • In his endeavor to find the causes of cachexia, Stephan Herzig, an expert in metabolism, took a closer look at the liver as the control center of metabolism for the first time. (bio-medicine.org)
  • Recognition of the complexity of cachexia is also of considerable importance, especially in its presentation with a variable combination of reduced food intake (with both primary and secondary etiologies) and abnormal metabolism (including tumor metabolism and host inflammation) in its underlying pathophysiology. (springer.com)
  • Definition of cancer cachexia: effect of weight loss, reduced food intake and systemic inflammation on functional status and prognosis. (springer.com)
  • The two main theories of the development of cancer cachexia are: Alteration of control loop: High levels of leptin, a hormone secreted by adipocytes, block the release of Neuropeptide Y(NPY), which is the most potent feeding-stimulatory peptide in the hypothalamic orexigenic network, leading to decreased energy intake, but high metabolic demand for nutrients. (wikipedia.org)
  • Cancer cachexia is an energy-wasting syndrome caused by decreased food intake (owing to marked anorexia) and increased energy expenditure. (nature.com)
  • Thus, it remains plausible that central melanocortin receptors may integrate a number of physiological signals that produce the combination of decreased energy intake and increased energy utilization that characterizes illness-induced cachexia. (aacrjournals.org)
  • To study the effects of a megestrol acetate liquid formulation (800 mg/d) on body weight, body composition, caloric intake, and mental outlook in patients with the acquired immunodeficiency syndrome (AIDS) who had cachexia. (annals.org)
  • Nevertheless, the increase in food intake does not prevent this negative outcome, and presently, there is no effective therapy for cachexia. (jcancer.org)
  • Cancer-related anorexia/cachexia (CAC) is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumour-derived catabolic factors, decreased food intake, and probably additional unknown factors, all play different roles. (semanticscholar.org)
  • Unexplained" weight loss that is not caused by reduction in calorific intake or exercise is called cachexia and may be a symptom of a serious medical condition. (wikipedia.org)
  • Although the exact cause of cachexia is not yet clearly understood, several studies have shown that inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α), interleukin 6 (IL-6), and interferon-gamma (IFN-γ) may play a role in the development of cachexia. (news-medical.net)
  • Various animal studies have proved that IL-6 has the potential to play a role in the development of cachexia, along with other factors. (news-medical.net)
  • These findings suggest that ZAG plays a predominant role in the development of cachexia, and thus, may represent a novel therapeutic target to block energy wasting and delay or prevent cachexia in cancer patients. (aacrjournals.org)
  • The exact mechanism in which these diseases cause cachexia is poorly understood, but there is probably a role for inflammatory cytokines, such as tumor necrosis factor-alpha (which is also nicknamed 'cachexin' or 'cachectin'), interferon gamma and interleukin 6, as well as the tumor-secreted proteolysis-inducing factor. (wikipedia.org)
  • Although the pathogenesis of cancer cachexia is poorly understood, multiple biologic pathways are known to be involved, including proinflammatory cytokines such as TNF-alpha, neuroendocrine hormones, IGF-1, and tumor-specific factors such as proteolysis-inducing factor. (wikipedia.org)
  • The results of this study suggest that elevated circulating levels of cytokines such as leptin may be an important cause of uremia-associated cachexia via signaling through the central melanocortin system. (jci.org)
  • Local adipokines produced by AT, circulating cytokines, and lipid mobilizing factors are collectively involved in adipose atrophy in cancer cachexia [ 13 , 14 ]. (hindawi.com)
  • Weight loss can also occur from cachexia, the increased metabolism of energy due to raised inflammatory cytokines, liver metastases and other factors seen in several advanced cancers. (springer.com)
  • This rise in cytokines can occur in response to chronic health conditions which trigger cachexia. (openpr.com)
  • On the basis of drug type, the market is segmented into medications that reduce cytokines in the body, stimulate appetite such as Dronabinol, mega sterol acetate and corticosteroids, or medicines that block hormones associated with cachexia. (openpr.com)
  • Bartolome R. Celli, MD, chief of pulmonary care at St. Elizabeth's Medical Center in Boston, says that cachexia occurs due to the "secretion of inflammatory cytokines such as tumor necrosis factor alpha, also known as cachexin. (everydayhealth.com)
  • In addition, proinflammatory cytokines such as TNFα and IL-6 have also been suggested to promote cancer cachexia ( Tisdale, 2009 ). (biologists.org)
  • ESKD is associated with an increase in inflammatory cytokines and can result in cachexia, with the loss of muscle and fat stores. (qub.ac.uk)
  • Sharma R, Anker SD (2002) Cytokines, apoptosis and cachexia:the potential for TNF antagonism. (springer.com)
  • These alterations are linked to pathways that can account for energy inefficiency associated with cancer cachexia. (lu.se)
  • Cachexia is infrequently identified or diagnosed, and rarely treated As the treatment of diseases such as cancer, CHF, COPD, HIV infection, and kidney disease becomes increasingly effective, the diagnosis and treatment of Cachexia associated with these diseases will become important goals to improve morbidity, mortality, and particularly, the quality of life. (1888pressrelease.com)
  • We tested the hypothesis that uremia-associated cachexia is caused by leptin signaling through the hypothalamic melanocortin receptor 4 (MC4-R). We performed either subtotal nephrectomy (N) or sham operations in WT, leptin receptor-deficient ( db/db ), and MC4-R knockout (MC4-RKO) mice. (jci.org)
  • Moreover, several pathways leading to cachexia have been well characterized in mice (discussed below). (biologists.org)
  • Finally, the availability of mice carrying mutations in genes that are associated with cachexia make mice an optimal model organism for investigating this condition. (biologists.org)
  • McDevitt TM, Todorov PT, Beck SA et al (1995) Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans. (springer.com)
  • Cariuk P, Lorite MJ, Todorov PT et al (1997) Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. (springer.com)
  • The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. (nih.gov)
  • These results demonstrate that pyocyanin reduces adipocyte differentiation and decreases body weight and fat mass in male and female mice, suggesting that pyocyanin may play a role in septic cachexia. (nih.gov)
  • The classical cancer cachexia model was established via transplantation of CT26 colon adenocarcinoma cells into BALB/c mice. (aacrjournals.org)
  • Two independent experiments showed that 30 mg/kg/d selumetinib prevented the loss of body weight in murine cachexia mice. (aacrjournals.org)
  • Fn14 signaling in the tumor, rather than host, is responsible for inducing this cachexia because tumors in Fn14- and TWEAK-deficient hosts developed cachexia that was comparable to that of wild-type mice. (uzh.ch)
  • In this review, we will describe the importance of oxidative stress in skeletal muscles, its sources, and how it can regulate protein synthesis/degradation imbalance, autophagy deregulation, increased myonuclear apoptosis, and mitochondrial dysfunction involved in cachexia. (hindawi.com)
  • However, other modes of protein degradation, such as lysosomal pathways or even cell death, might also be involved in cachexia. (biologists.org)
  • Protein loss in cancer cachexia. (springer.com)
  • protein turnover in cancer -associated cachexia . (zanran.com)
  • Energy wasting in cachexia is caused by excessive lipid and protein turnover in the body, browning of white adipose tissue (WAT), and futile metabolic cycling such as glucose recycling between the liver and tumor. (aacrjournals.org)
  • One of the features of cachexia is the loss of muscle mass, characterized by an imbalance between protein synthesis and protein degradation. (sigmaaldrich.com)
  • Researchers at the Institute for Diabetes and Cancer (IDC) at Helmholtz Zentrum München have identified the AMP-activated protein kinase (AMPK) as the central enzyme in cancer cachexia. (technologynetworks.com)
  • It was also demonstrated that both placebo and experimental amino acid mixtures significantly increased FFM, total body protein, arms and legs lean mass, and measures of physical function in rheumatoid arthritis patients but HMB/ARG/GLN supplementation was not superior to placebo in reversing rheumatoid cachexia (Marcora et al. (wikipedia.org)
  • Note that PEM may be secondary to other conditions such as chronic renal disease or cancer cachexia in which protein energy wasting may occur. (wikipedia.org)
  • Exceedingly high BCKD complex activity increases branched-chain amino acid catabolism and protein degradation in skeletal muscle, which is a distinctive feature for cachexia. (wikipedia.org)
  • He then studied the relationship between protein and vitamin A which led to the finding that the amount, as well as biological value, of dietary protein are important in the process of converting carotene to vitamin A. Other studies dealt with metabolic changes during cachexia of tumor-bearing animals. (wikipedia.org)
  • If a person is physically capable, resistance training using weights or resistance bands are helpful in treating muscle loss in cachexia. (openpr.com)
  • Can the use of creatine supplementation attenuate muscle loss in cachexia and wasting? (nih.gov)
  • Cachexia, a hypercatabolic state defined as accelerated loss of skeletal muscle in the context of a chronic inflammatory response, can occur in the setting of advanced cancer as well as in chronic infection, acquired immunodeficiency syndrome (AIDS), heart failure, rheumatoid arthritis, and chronic obstructive pulmonary disease [ 1 ]. (uptodate.com)
  • Cachexia (loss of weight) has been reported by people with hiv infection, pain, osteoporosis, multiple myeloma, rheumatoid arthritis ( latest reports from 4,294 Cachexia patients ). (ehealthme.com)
  • Rheumatoid Cachexia: What Is It and Why Is It Important? (jrheum.org)
  • Rheumatoid cachexia (RC) is common, probably underappreciated, and incompletely understood. (jrheum.org)